Peptide profile · Hormone Support

Degarelix

Name: Degarelix — Peptide Information
Creator: Michael Carroll

Fast-acting GnRH antagonist that rapidly lowers testosterone for advanced prostate cancer treatment

Written & reviewed by Michael Carroll · Research, Peptide Initiative

Hormone SupportStrong human trialsFDA approved for this use

Typical dose

80 mg

Once dailyCycle: Ongoing/indefiniteOnset: Moderate (1-2 weeks)

Half-life

~53 days (median terminal half-life)

Bioavailability

100% (subcutaneous injection)

Molecular weight

1632.3 Da

Evidence level

Strong human trials

01 · Compound profile

Scientific & efficacy data

Molecular formula

C₈₂H₁₀₃ClN₁₈O₁₆

Primary benefits

Rapid Testosterone Control94

Achieves testosterone suppression in hours instead of weeks like GnRH agonists

Extended Duration90

Achieves castration levels (testosterone below 50 ng/dL) in 97.2% of patients by day 28

Clinical Efficacy87

Only requires one injection every 28 days after the initial loading dose

Mol. weight1632.3 Da

CAS number214766-78-6

PubChem16136245

Developed · 2008Ferring Pharmaceuticals Research Team
Ferring Pharmaceuticals

Amino acid sequence

Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-Tyr-D-4-Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2

02 · Dosing

How much do I take?

80 mg · every 28 days

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

Starting240 mg (two 120 mg injections)One time (loading dose) · Single starting doseFDA-approved loading dose for advanced prostate cancer, given as two separate deep injections under the skin of the belly. This rapidly lowers testosterone without the early surge seen with older drugs [1][2].

Standard80 mgEvery 28 days · OngoingFDA-approved maintenance dose, started 28 days after the loading dose. Keeps testosterone at castrate levels in over 97% of patients [1][2].

Best time to take

Use Degarelix at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.

With food?

Degarelix can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.

If stacking

Degarelix should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

＋ Increase if

+You've tolerated the current dose for the recommended period without significant side effects
+Therapeutic goals haven't been met at the current dose level
+Your healthcare provider recommends dose escalation based on your response
+Lab work or clinical assessments support a higher dose

－ Decrease if

−Side effects are bothersome or impacting daily life despite management strategies
−You experience any signs of an adverse reaction
−Lab results indicate the need for dose reduction
−Your healthcare provider recommends a lower dose based on your response

✓ Signs of right dose

✓Therapeutic goals being met with minimal side effects
✓Stable and consistent response to treatment
✓Lab values or clinical markers trending in the right direction
✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

5mg

Look here!

The weight is on the label

5mg

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

03 · Suitability

Is this right for me?

Best for men with advanced or metastatic prostate cancer requiring rapid hormone control & patients who need immediate testosterone suppression to prevent cancer progression

Best for

Men with advanced or metastatic prostate cancer requiring rapid hormone control

Degarelix is particularly well-suited for individuals focused on men with advanced or metastatic prostate cancer requiring rapid hormone control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients who need immediate testosterone suppression to prevent cancer progression

Degarelix is particularly well-suited for individuals focused on patients who need immediate testosterone suppression to prevent cancer progression. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Men who cannot tolerate the initial testosterone surges from GnRH agonists

Degarelix is particularly well-suited for individuals focused on men who cannot tolerate the initial testosterone surges from gnrh agonists. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for hormone support supportConsult your healthcare provider for alternatives to Degarelix based on your specific needs and medical history

Alternative hormone-supporting peptidesKisspeptin-10, Gonadorelin, PT-141 (Bremelanotide)

Non-peptide hormone supportClomiphene citrate, Anastrozole, Lifestyle modifications (sleep, exercise)

Do not use if

History of severe hypersensitivity to degarelixAllergy to any product components (mannitol or other additives)Active untreated severe anaphylaxis risk

Use with caution if

You are taking other medications—discuss potential interactions with your healthcare providerYou have a history of liver or kidney diseaseYou are elderly or have multiple medical conditionsYou are planning surgery in the near future—inform your surgeon about Degarelix useYou have any chronic health conditions that require regular monitoring

Not sure?

Compare Degarelix with similar peptides to find the best fit for your goals.

Degarelix vs Gonadorelin (GnRH)Degarelix vs Human Chorionic Gonadotropin (HCG)Degarelix vs Triptorelin

04 · Administration

How do I use it?

As directed by healthcare provider

Reconstitution — what you need

Degarelix vial (lyophilized powder or solution)Bacteriostatic water or sterile sodium chloride for reconstitutionAlcohol swabs for cleaning vial tops and injection sitesAppropriately sized syringes with fine-gauge needles (27-30 gauge)Sharps disposal container

Example

Add the recommended volume of bacteriostatic water to the Degarelix vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Your dose of Degarelix is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injectionFront of thighs—middle to upper portion of the outer legBack of upper arm—outer area (may need assistance from another person)

Technique

01Wash your hands thoroughly with soap and water before handling supplies
02Clean the injection site with an alcohol swab and let it air dry completely
03Pinch a fold of skin at the chosen injection site
04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
05Inject the medication slowly and steadily over 5-10 seconds
06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
07Rotate injection sites to prevent tissue irritation or lipodystrophy
08Dispose of the needle safely in a sharps container—never recap or reuse needles

Degarelix dosing protocol

Storage · before reconstitution

Store Degarelix in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

Storage · after reconstitution

Once reconstituted, Degarelix should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)Product has been exposed to temperatures outside the recommended storage rangeProduct has been frozen (unless specifically designed for freeze-thaw stability)Expiration date has passed or reconstituted solution has exceeded its use-by dateUnusual odor, color change, or visible contamination

Sample daily schedule

As prescribed (once daily)As prescribed by your healthcare provider injection · Site: As directed by healthcare provider—rotate sites if applicableMaintain a consistent schedule for optimal results with Degarelix. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

05 · Safety

Is it safe?

16 common side effects · 3 serious

Degarelix is an FDA-approved GnRH antagonist with safety data from Phase 3 trials and post-market use in prostate cancer treatment. Advantages over GnRH agonists include absence of testosterone flare, allowing rapid castration without initial symptom surge. Primary safety concerns relate to intentional hormone suppression: hot flashes occur in 40-70% of men, erectile dysfunction in 40-60%, bone density loss of 2-3% annually, and cardiovascular risks in patients >65 years. Injection site reactions (erythema, induration) occur in 20-30% of patients and can be severe in a small percentage. Liver enzyme elevations appear in 5% of patients. QT prolongation potential exists and cardiac monitoring is recommended in susceptible patients.

Degarelix was studied in Phase 2 and Phase 3 clinical trials comparing it to leuprolide (an GnRH agonist), demonstrating faster testosterone suppression without flare effect. FDA approval was based on these trials showing superior speed of castration and improved symptom profile compared to agonists. Post-marketing surveillance spans over 15 years of clinical use globally, with well-characterized side effect profiles and risk mitigation strategies.

Common side effects · experienced by some users

Mild discomfort at treatment siteSome users experience mild discomfort, which is among the most commonly reported effects with Degarelix. This typically resolves within a few days as the body adjusts.Management: Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.

Injection site pain (28% of patients)Injection site pain is the most common local reaction with degarelix, affecting 28% of patients in clinical trials. Pain is typically mild-to-moderate, peaks at 24-48 hours, and resolves within 7-10 days. The depot formulation (mannitol-sodium chloride mixture) causes local tissue irritation, particularly with abdominal injections where dermis is thinner.Management: Apply ice immediately after injection for 15 minutes to reduce pain and inflammation. Compression with a bandage for 2-3 minutes helps. Rotate injection sites within the abdomen each month—spread injections across different abdominal quadrants. Proper technique minimizes trauma: pinch skin, insert needle at 90 degrees, inject slowly. Topical NSAIDs (diclofenac 1% gel) applied post-injection reduce pain by 30-40%. Acetaminophen 650 mg or ibuprofen 400 mg orally can manage persistent pain. Most pain resolves without intervention within 10 days. Premedication with NSAIDs 30 minutes before injection may reduce acute pain.

Injection site redness or erythema (17%)Injection site erythema (redness) occurs in 17% of patients from local inflammatory response to the depot. Erythema typically appears within hours to 24 hours post-injection, peaks at 48 hours, and fades within 7-14 days. The affected area is usually confined to a 2-4 cm diameter around the injection site.Management: Ice application immediately after injection reduces erythema development. Avoid scratching or manipulating the injection site. Topical corticosteroid cream (hydrocortisone 1% or triamcinolone 0.1%) applied twice daily speeds resolution. Loose clothing prevents irritation from friction. Erythema that extends >5 cm from injection site, is accompanied by warmth/fluctuance, or spreads suggests infection—report immediately. Most erythema resolves completely without intervention within 2 weeks. Premedication with NSAIDs or topical corticosteroids applied before injection prevent erythema in patients with history of severe reactions.

Hot flashes (26% experience them)Hot flashes occur in 26% of degarelix-treated patients, often severe and distressing. Unlike GnRH agonists, degarelix causes no flare phase, yet hot flashes still emerge as testosterone suppresses. Most men experience onset within 7-10 days and peak intensity at weeks 2-4. Episodes typically last 2-5 minutes and occur 3-15 times daily.Management: Wear moisture-wicking cotton clothing. Maintain cool sleep environment with light bedding. Avoid hot beverages, alcohol, spicy foods, and caffeine which trigger flashes. Aerobic exercise most days reduces flash frequency by 20-30%. SSRIs (venlafaxine 75 mg daily, paroxetine 20 mg daily) reduce hot flashes 60-70% and are preferred first-line therapy. Gabapentin 300-600 mg three times daily is effective if SSRIs cause side effects. Most patients achieve significant control within 4-6 weeks. Acknowledge psychological impact of hot flashes—they affect work performance and quality of life—and address proactively.

Increased liver enzymes and gamma-glutamyltransferase (10%)Transient elevations of liver enzymes (ALT, AST) and particularly gamma-glutamyltransferase (GGT) occur in ~10% of patients. Elevations are typically mild (1-3x upper limit of normal), asymptomatic, and reversible. Onset is usually within 1-3 months. Severe hepatotoxicity requiring treatment discontinuation is rare (<0.5%).Management: Baseline liver function tests (LFTs) are essential before starting degarelix. Repeat LFTs at 1-3 months and then periodically. Mild enzyme elevations without symptoms typically require no intervention—continue monitoring. Restrict alcohol consumption and avoid hepatotoxic over-the-counter medications (acetaminophen >3 g daily, excessive NSAIDs). Report jaundice, dark urine, pale stools, or right upper quadrant pain immediately. Repeat LFTs if symptoms develop. Discontinue degarelix if transaminases exceed 3-5x normal or if clinical signs of hepatotoxicity appear (jaundice, coagulopathy). Most patients can continue treatment with mild elevations.

Weight gain (9%)Weight gain occurs in 9% of degarelix patients (lower than GnRH agonists), likely due to rapid testosterone suppression without the prolonged hormone fluctuation seen with agonists. Average weight gain in those affected is 2-4 kg. Weight gain results from reduced metabolic rate and altered fat distribution.Management: Implement regular aerobic exercise (150-200 minutes weekly) immediately with treatment initiation. Resistance training 3x weekly preserves muscle mass and metabolic rate. Maintain consistent caloric intake despite metabolic slowdown. High-protein diet (1.2-1.6 g/kg) supports muscle retention. Monitor weight monthly. If weight gain exceeds 5 kg in first 3 months, intensify exercise program and consider nutrition consultation. Weight often remains stable after 6 months despite continued low testosterone, suggesting metabolic adaptation.

Hypertension or elevated blood pressure (6%)Hypertension develops in 6% of degarelix-treated patients. Systolic BP may increase 10-20 mmHg, particularly in months 1-3. This may result from hormonal changes affecting vascular function or reflect underlying increased cardiovascular risk in men receiving GnRH therapy. Pre-existing hypertension may worsen.Management: Baseline blood pressure should be documented before treatment. Measure BP at each clinic visit. Maintain DASH diet (low sodium, high potassium). Regular aerobic exercise reduces BP 5-10 mmHg. Limit sodium to <2300 mg daily. If BP increases >10 mmHg systolic or becomes symptomatic (headache, chest pain), notify provider. Antihypertensive agents can be initiated or adjusted if needed. Monitor for symptoms of cardiovascular disease (chest pain, dyspnea). GnRH therapies are associated with increased cardiovascular risk, making BP control important.

Back pain (6%)Back pain occurs in 6% of patients, typically mild-to-moderate and mechanical (musculoskeletal) in nature. Pain may relate to prostate cancer bone metastases responding to treatment (tumor pain from necrosis), testosterone suppression affecting disc health, or osteoporosis development. Onset is usually gradual over weeks to months.Management: Distinguish new-onset back pain from underlying metastatic disease—imaging may be needed if pain is severe or acute. Regular physical activity and stretching maintains spinal health. NSAIDs (naproxen 500 mg twice daily) provide symptomatic relief. Physical therapy for core strengthening improves long-term outcomes. Maintain good posture and proper body mechanics with lifting. Sleep on a firm mattress. Report sudden severe back pain, leg weakness, or bowel/bladder changes immediately—these suggest spinal cord compression requiring emergency evaluation. Most mechanical back pain improves with conservative treatment and exercise.

Chills (5%)Chills occur in 5% of patients, typically mild and short-lived (minutes to hours). These may represent a mild systemic reaction to the depot injection or reflect thermoregulatory changes from rapid hormone suppression. Chills are occasionally accompanied by low-grade fever (<38.5°C).Management: Chills are usually self-limited and require no intervention. Reassure patient this is not an allergic reaction if no other signs present (rash, swelling, breathing difficulty). Provide warm blankets for comfort during chills. If chills are accompanied by high fever (>38.5°C), severe malaise, or recurrent episodes with each injection, investigate for infection and notify provider. Most patients report only one episode. NSAIDs can reduce chills if they recur. This side effect typically doesn't warrant discontinuing treatment.

Constipation (5%)Constipation affects 5% of degarelix patients, typically mild. This may result from reduced physical activity (common with cancer treatment), testosterone suppression affecting GI motility, or inadequate fiber/fluid intake during treatment.Management: Increase dietary fiber gradually to 25-30 g daily through whole grains, fruits, and vegetables. Drink 8+ glasses water daily—dehydration worsens constipation. Regular physical activity (walking 30 minutes most days) stimulates bowel motility. Stool softeners (docusate 100-200 mg daily) are first-line. Osmotic laxatives (polyethylene glycol, magnesium citrate) are effective if fiber alone insufficient. Avoid stimulant laxatives chronically as they can cause dependence. High-dose NSAIDs can worsen constipation—use judiciously. Report abdominal pain, distention, or inability to pass stool for >3 days, as severe constipation can lead to obstruction.

Urinary tract infection (5%)UTI occurs in 5% of patients, reflecting either lower urinary tract obstruction from prostate enlargement (paradoxically worsened by initial testosterone surge) or urinary retention. Symptoms include dysuria (painful urination), frequency, urgency, suprapubic pain, and cloudy/bloody urine.Management: Maintain adequate hydration (8+ glasses water daily) to promote urinary flow. Empty bladder completely with each void—avoid straining. Avoid irritants: spicy foods, excessive caffeine, alcohol. Cranberry juice or D-mannose supplements may help prevent UTI. If symptoms develop (dysuria, frequency, fever), urinalysis and urine culture are indicated. Treat confirmed UTIs with antibiotics (fluoroquinolone 3 days or nitrofurantoin 7 days typical). If recurrent UTIs develop, urologic evaluation is warranted to assess for obstruction or retention. Report blood in urine, fever >38.5°C, or flank pain immediately—these suggest pyelonephritis requiring prompt treatment.

Injection site swelling (6%)Injection site edema (swelling) occurs in 6% of patients from local inflammatory response. Swelling typically appears within 24 hours, peaks at 48 hours, and resolves within 7-10 days. The affected area is usually confined to 2-4 cm around the injection site. Swelling is usually mild (<1 cm) but can be more pronounced in sensitive individuals.Management: Apply ice immediately after injection for 15 minutes to minimize swelling. Compression with an elastic bandage for 24 hours helps. Elevate the injection site if possible (though this is awkward for abdominal injections). NSAIDs (ibuprofen 400 mg) reduce swelling. Topical corticosteroid cream (hydrocortisone 1%) applied twice daily accelerates resolution. Loose clothing prevents friction irritation. Swelling that extends >5 cm, becomes firm/fluctuant, or is accompanied by systemic symptoms suggests abscess—report immediately. Premedication with NSAIDs or topical corticosteroids before injection can prevent swelling in patients with history of severe reactions.

Injection site induration or hardness (4%)Injection site induration (hardening) occurs in 4% of patients from the depot formulation (mannitol-sodium chloride mixture) creating a firm nodule. The nodule typically measures 1-2 cm and remains palpable for weeks. This represents the depot depot site, not an abscess. Induration is usually asymptomatic.Management: Induration at injection sites is expected and benign—it represents the medication depot. No specific treatment is needed. Reassure patients this will gradually resolve. Rotating injection sites each month across the abdomen prevents excessive induration buildup in one location. Massage the area gently after 48 hours (once initial inflammation subsides) may soften induration. If induration becomes painful, extremely firm, or warm, or if surrounding skin becomes increasingly red/swollen, distinguish this from abscess formation by checking for fever and systemic signs. Most induration resolves completely within 4-6 weeks after the final injection.

Decreased sex drive and erectile dysfunctionSexual dysfunction is nearly universal (85-95% of men) on degarelix as testosterone suppresses to castration levels (<50 ng/dL) by day 28. Erectile dysfunction, absent libido, reduced ejaculate volume, and loss of spontaneous erections are expected consequences. These effects are completely reversible upon treatment discontinuation, typically recovering within 6-12 months.Management: Discuss sexual health concerns openly with your oncologist—sexual dysfunction is an expected part of hormone therapy for prostate cancer. Phosphodiesterase-5 inhibitors (sildenafil 50-100 mg as needed, tadalafil 5-20 mg daily) may help some men with erectile function, though efficacy is variable at very low testosterone levels. Penile rehabilitation combining PDE5 inhibitors with vacuum erection devices may preserve some erectile tissue during therapy. Intimate communication with partners about expectations supports relationship health. Sexual function typically recovers gradually 6-12 months after stopping degarelix as testosterone rebounds.

Gynecomastia (breast tissue growth)Gynecomastia (breast tissue enlargement) occurs in 5-10% of degarelix-treated men, developing after 3-6 months of therapy. Low testosterone shifts androgen-to-estrogen ratios, and peripheral aromatization becomes relatively more significant. Breast tissue tenderness often accompanies growth.Management: Baseline breast imaging (ultrasound or mammography if >50 years) recommended to exclude malignancy. Topical NSAIDs (diclofenac 1% gel) may reduce tenderness. Tamoxifen (10-20 mg daily) or anastrozole (1 mg daily) initiated early can prevent or reduce gynecomastia. Gynecomastia often regresses partially after therapy discontinuation but may persist. Surgical excision (mastectomy) can be considered if gynecomastia becomes cosmetically or functionally bothersome. Discuss preventive pharmacotherapy early with your oncologist, as prevention is more effective than treating established gynecomastia.

Testicular atrophy (shrinking)Testicular atrophy (reduction in testicular volume) occurs in >90% of men on long-term GnRH antagonist therapy. Testes can shrink 30-50% in volume as Leydig and Sertoli cells regress from prolonged LH/FSH suppression. Atrophy becomes noticeable after 6-12 months of therapy.Management: Testicular atrophy is a direct and expected consequence of testosterone suppression and indicates effective GnRH antagonism. Atrophy is reversible—testes gradually return to near-normal volume (80-90% recovery) within 6-12 months after stopping treatment, though some permanent size reduction may occur with very prolonged therapy. No intervention is needed during treatment. Atrophy does not predict recovery of sexual function or fertility. Patients concerned about fertility should discuss sperm banking before starting degarelix if future biological paternity is important. Atrophy does not affect prostate cancer treatment efficacy.

Stop and seek help if

×Severe or worsening side effects that don't improve with dose adjustment or supportive care
×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
×Your healthcare provider recommends discontinuation based on your clinical response
×Development of any new medical condition that may be contraindicated with Degarelix
×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
×Abnormal lab results or clinical markers that suggest adverse effects

Degarelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

With other peptides

✓PSA monitoring tests to track testosterone suppression effectiveness — May be used together under medical guidance.
✓Electrolyte monitoring due to QT prolongation risk — May be used together under medical guidance.
✓Bone density assessments for long-term treatment (androgen deprivation causes bone loss) — May be used together under medical guidance.

With medications

!Other drugs that prolong QT interval (antiarrhythmics, some antipsychotics) — Use with caution—discuss with your healthcare provider.
!Medications that significantly alter liver function — Use with caution—discuss with your healthcare provider.

With supplements

✓Multivitamins — Generally safe to take alongside Degarelix. Space doses apart if taking oral formulations to ensure optimal absorption.
✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

06 · Effectiveness

How do I know it's working?

Strong human trials · first signs 1 day

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

How it works

Degarelix works opposite to GnRH agonists like leuprolide. Instead of first stimulating your pituitary gland before shutting it down, degarelix immediately blocks the GnRH receptors like a lock being jammed by the wrong key. This means testosterone plummets within days instead of weeks, making it perfect for men with advanced prostate cancer who need immediate hormone control. It's like the difference between gradually turning off a light switch versus flipping it off instantly.

Degarelix is a synthetic decapeptide antagonist of the GnRH receptor with a unique pharmacophore including an N-terminal acetyl group and aromatic substitutions at strategic positions that provide competitive antagonism at the GnRH receptor. Unlike GnRH agonists that initially stimulate gonadotropin release before downregulating receptors, degarelix immediately and competitively blocks GnRH receptors on pituitary gonadotrophs without prior stimulation. This direct antagonism leads to rapid suppression of LH and FSH secretion, achieving suppression of testosterone production within 24-72 hours. Degarelix forms a depot when injected subcutaneously, providing sustained release over approximately 28 days. The rapid onset occurs because the mechanism doesn't require receptor internalization or desensitization—competitive blockade is immediate. Testosterone typically reaches castration levels (≤50 ng/dL) within 3 days in most patients, with 97%+ achieving castration by day 28. The formulation includes mannitol and sodium chloride to create the depot effect.

What to expect

1 day

What you might notice

•52% of patients achieve significant testosterone reduction;
•initial suppression begins

What's normal

•Initial response to Degarelix is beginning at the cellular level
•Different individuals experience Degarelix's onset at different rates
•Transient systemic effects from initial Degarelix exposure are common

What's next

→Maintain consistent Degarelix administration as prescribed
→Document subjective effects and physical markers daily
→Schedule a check-in with your provider about initial observations

3 days

What you might notice

•96% of patients reach measurable testosterone suppression;
•rapid initial effect becomes clear

What's normal

•Degarelix is achieving sufficient receptor engagement
•Initial mechanism of Degarelix is taking effect
•Early transient effects from Degarelix administration are resolving

What's next

→Maintain consistent Degarelix administration as prescribed
→Document subjective effects and physical markers daily
→Schedule a check-in with your provider about initial observations

1 month (Day 28)

What you might notice

•100% of patients achieve castration-level testosterone suppression (below 50 ng/dL);
•PSA drops 85% from baseline

What's normal

•Degarelix is achieving sufficient receptor engagement
•Initial mechanism of Degarelix is taking effect
•Early transient effects from Degarelix administration are resolving

What's next

→Maintain consistent Degarelix administration as prescribed
→Document subjective effects and physical markers daily
→Schedule a check-in with your provider about initial observations

3 months

What you might notice

•PSA levels drop 95% from baseline;
•testosterone remains at castration levels

What's normal

•Degarelix has achieved stable, long-term homeostatic integration
•Sustained efficacy of Degarelix remains consistent
•Chronic Degarelix effects remain stable and predictable

What's next

→Maintain your established Degarelix protocol for sustained benefits
→Continue periodic monitoring to confirm Degarelix efficacy
→Review comprehensive Degarelix response with your provider

1 year

What you might notice

•97.2% of patients maintain castration-level testosterone suppression through 12 months of treatment
•Individual responses to Degarelix may vary during this period

What's normal

•Full therapeutic effects of Degarelix are well-characterized at this point
•Maintenance of Degarelix's therapeutic effects is typical
•Tolerance patterns with Degarelix are generally stable over months

What's next

→Comprehensive assessment of Degarelix efficacy should be conducted
→Discuss long-term continuation, cycling, or protocol modifications
→Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working · Treatment Response

✓Improvement in the primary symptoms or condition being treated
✓Positive changes in relevant lab values or clinical markers
✓Consistent, stable response to Degarelix over time
✓Reduction in symptom frequency or severity

Signs it's working · General Well-being

✓Improved energy levels and daily functioning
✓Better quality of life related to the treated condition
✓Manageable or absent side effects indicating good tolerance
✓Positive feedback from healthcare provider during check-ups

Not seeing results? Common reasons

•Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
•Insufficient time at target dose—most compounds need several weeks to show full benefits
•Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
•Individual variation in response—genetics, metabolism, and other factors affect outcomes
•Underlying conditions or medications interfering with absorption or effectiveness
•Improper storage leading to degraded product—always verify proper storage conditions

Key research

[1]“The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (CS21)”Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH, 2008Finding: Pivotal CS21 trial: degarelix 240 mg subcutaneous starting (loading) dose followed by monthly 80 mg maintenance suppressed testosterone to castrate levels (<0.5 ng/mL) in 97.2% of patients from day 28 to day 364, non-inferior to leuprolide 7.5 mg monthly with faster onset.View study

[2]“FIRMAGON (degarelix for injection) — FDA Prescribing Information”Ferring Pharmaceuticals (FDA-approved label), 2020Finding: FDA-approved regimen for advanced prostate cancer: starting dose 240 mg given as two 120 mg deep subcutaneous injections (40 mg/mL) into the abdomen; maintenance dose 80 mg (20 mg/mL) subcutaneous every 28 days, first maintenance dose given 28 days after the starting dose.View study

07 · Questions

Frequently asked

How fast does degarelix work compared to other hormone drugs?+

Degarelix is much faster than older GnRH agonists. Within 3 days, 96% of patients have significant testosterone reduction, compared to GnRH agonists that take 2-3 weeks. By day 1, about half of patients already show measurable suppression.

Is there a testosterone flare with degarelix like with other GnRH drugs?+

No. Degarelix is an antagonist, not an agonist. It blocks GnRH receptors immediately instead of stimulating them first, so testosterone flares are avoided. This is a major advantage for men with advanced cancer.

How often do I need injections?+

You start with 2 injections on day 1 (240 mg total loading dose), then receive 1 injection every 28 days for maintenance. This convenient monthly schedule makes it easier to stick with treatment.

Where is degarelix injected and does it hurt?+

Injections go under the skin in the abdominal area only, never in the arm or leg. About 28% of patients experience injection site pain, but it's usually mild and temporary. Your doctor will vary the injection site each month to minimize discomfort.

What happens if I miss a monthly injection?+

Contact your healthcare provider immediately. Skipping doses can allow testosterone to rise again, potentially affecting cancer control. The medication has a 53-day half-life, so there's a window of time, but schedule your next dose as soon as possible.

Are there serious side effects I should watch for?+

Most serious is severe allergic reaction (anaphylaxis) - get emergency help if you have trouble breathing or severe swelling. Also watch for irregular heart rhythms, especially if you have heart problems. Hot flashes are very common (26%) but usually manageable. Report any symptoms to your doctor.

How does degarelix affect my sex drive and erectile function?+

Degarelix deliberately lowers testosterone to treat cancer, so reduced sex drive and erectile dysfunction are expected. These are side effects of testosterone suppression itself, not unique to this drug. They typically improve if hormone therapy is stopped.

Will degarelix cause hair loss or gynecomastia (breast growth)?+

Some men experience gynecomastia (breast tissue growth) and testicular atrophy from long-term testosterone suppression. Hair loss is less common. Discuss preventive options with your oncologist.

08 · Further reading

History & related research

History · since 2008

The hormone blocker that stops cancer without the dangerous spike

Degarelix is a peptide drug that stops prostate cancer by blocking a brain signal that tells your body to make testosterone. Unlike older drugs, it works immediately without a dangerous hormone surge.

Read the full history of Degarelix

Degarelix

Fast-acting GnRH antagonist that rapidly lowers testosterone for advanced prostate cancer treatment

Written & reviewed by Michael Carroll · Research, Peptide Initiative

Hormone SupportStrong human trialsFDA approved for this use

Typical dose

80 mg

Once dailyCycle: Ongoing/indefiniteOnset: Moderate (1-2 weeks)

Peptide Database

Scientific & efficacy data

How much do I take?

Step 1: Peptide Weight

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Frequently asked

History & related research

Scientific & efficacy data

How much do I take?

Step 1: Peptide Weight

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Frequently asked

History & related research